Capricor Therapeutics (CAPR) Revenue (2011 - 2024)
Capricor Therapeutics (CAPR) posted quarterly Revenue of $11.1 million for Q4 2024, down 7.92% year-over-year from $12.1 million in Q1 2024, and up 392.14% quarter-over-quarter from $2.3 million in Q3 2024.
Capricor Therapeutics (CAPR) Revenue (2011 - 2024) Analysis & Trends
Capricor Therapeutics' Revenue history runs 13 years deep, the most recent figure standing at $11.1 million for Q4 2024.
- In Q4 2024, Revenue fell 7.92% year-over-year to $11.1 million; the TTM figure through Sep 2025 stood at $11.1 million (down 60.7% YoY), while the FY2024 annual figure was $22.3 million, down 11.55% from the prior year.
- Revenue for Q4 2024 stood at $11.1 million, up from $2.3 million in the prior quarter.
- The five-year high for Revenue was $12.1 million in Q4 2023, with the low at $16863.0 in Q3 2020.
- The 5-year median for Revenue is $1.9 million (2022), against an average of $3.5 million.
- The sharpest annual moves came in 2020 and 2023: Revenue tumbled 88.13% in 2020, then surged 1159.3% in 2023.
- Capricor Therapeutics' Revenue stood at $57830.0 in 2020, then jumped by 252.9% to $204082.0 in 2021, then jumped by 370.35% to $959903.0 in 2022, then soared by 1159.3% to $12.1 million in 2023, then decreased by 7.92% to $11.1 million in 2024.
- Business Quant data shows CAPR's Revenue at $11.1 million in Q4 2024, $2.3 million in Q3 2024, and $4.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 11.13 Mn |
| Sep 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 3.97 Mn |
| Mar 31, 2024 | 10.00 Mn |
| Dec 31, 2023 | 12.09 Mn |
| Sep 30, 2023 | 6.19 Mn |
| Jun 30, 2023 | 3.92 Mn |
| Mar 31, 2023 | 2.99 Mn |
| Dec 31, 2022 | 959,903.00 |
| Sep 30, 2022 | 1.59 Mn |
| Jun 30, 2021 | 204,082.00 |
| Mar 31, 2021 | 40,816.00 |
| Dec 31, 2020 | 57,830.00 |
| Sep 30, 2020 | 16,863.00 |
| Jun 30, 2020 | 49,864.00 |
| Mar 31, 2020 | 185,693.00 |
| Dec 31, 2019 | 222,100.00 |
| Sep 30, 2019 | 142,071.00 |
| Jun 30, 2019 | 410,353.00 |
| Mar 31, 2019 | 230,504.00 |